TP53 and hepatocellular carcinoma: Concordantly, IP6 substantially reduced α-fetoprotein (AFP) release in human hepatoma cells, reinforcing that IP6 acted on tumor-associated markers beyond tumor suppressors such as p53, but also secreted oncofetal proteins across diverse models [26].